-
Hainan Poly Pharm’s Novel Nanomedicine PLAT001 Gets US FDA Approval for Clinical Trials
•
Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, has announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its novel injectable PLAT001, intended for the treatment of advanced or metastatic solid tumors, including pancreatic cancer. PLAT001, a groundbreaking nanomedicine,…
-
CareRay Digital Medical Technology to Acquire 30% Stake in UK’s ISDI for USD 15.2 Million
•
CareRay Digital Medical Technology Co., Ltd, a company based in Suzhou (SHA: 688607), has announced plans to acquire a 30% stake in UK-headquartered ISDI Ltd for a consideration of GBP 12 million (USD 15.2 million). ISDI specializes in the research and development, manufacturing, and marketing of CMOS X-ray detectors and…
-
Jiangsu Hengrui’s SHR-A2009 Earns Fast-Track Status for Metastatic NSCLC Treatment
•
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that its in-house developed antibody-drug conjugate (ADC), SHR-A2009, has received fast-track status. This designation underscores the drug candidate’s potential as a treatment for metastatic non-small cell lung cancer (NSCLC) patients with EGFR mutations who have progressed after treatment with third-generation EGFR…
-
Grifols Sells 20% Stake in Shanghai RAAS to Haier Group for USD 1.8 Billion
•
Grifols (BME: GRF; NASDAQ: GRFS), a Spanish pharmaceutical company, has announced the formation of an alliance with Haier Group, a Chinese electronics and appliances giant. Under the agreement, Grifols will sell a 20% equity stake in Shanghai RAAS (SRAAS) for RMB 12.5 billion (USD 1.8 billion). Following the transaction, Grifols…
-
MicroPort CardioFlow Medtech to Acquire Controlling Stake in La Ronda for USD 20 Million
•
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG: 0853), has announced that a conditional agreement has been reached to acquire a 51% stake in fellow Chinese firm La Ronda for a cash consideration of RMB 141 million (USD 20 million). La Ronda, based…
-
P-Cure Initiates Construction of Affordable Proton Therapy Center in China’s Shandong Province
•
P-Cure, an Israeli company specializing in proton therapy, has commenced construction on a proton therapy center in Taian city, Shandong province, China, according to a report by the South China Morning Post. The development is being carried out by P-Cure’s Chinese subsidiary, SIHA, with the goal of providing precision cancer…
-
Medilink Therapeutics Secures Multi-Billion Dollar Deal with Roche for c-MET Targeting ADC
•
Medilink Therapeutics, a Suzhou-based biopharmaceutical company, has entered into a global collaboration and licensing agreement with Swiss pharmaceutical giant Roche concerning YL211, an antibody drug conjugate (ADC) targeting c-Mesenchymal-epithelial transition factor (c-MET) for the development of a treatment for solid tumors. This agreement marks Medilink’s fifth out-license deal for ADC…
-
Beijing Avistone Pharmaceuticals Raises RMB 1 Billion in Series B Funding to Accelerate Drug Development
•
Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd, based in China, has successfully closed its Series B funding round, raising RMB 1 billion (approximately USD 140 million). The round was jointly led by CS Capital and IDG Capital, with additional contributions from YanChuang Group, Cathay Capital, and existing investor Bain Capital. The…
